The signaling of Toll-like receptors (TLRs) induces host defense against microbial invasion. Protein posttranslational modifications dynamically shape the strength and duration of the signaling pathways. It is intriguing to explore whether deSUMOylation could modulate the TLR signaling. Here we identified SUMO-specific protease 6 (SENP6) as an intrinsic attenuator of the TLR-triggered inflammation. Depletion of SENP6 significantly potentiated the NF-kB-mediated induction of the proinflammatory genes. Consistently, SENP6-knockdown mice were more susceptible to endotoxin-induced sepsis. Mechanistically, the small ubiquitin-like modifier 2/3 (SUMO-2/3) is conjugated onto the Lysine residue 277 of NF-kB essential modifier (NEMO/IKKc), and this impairs the deubiquitinase CYLD to bind NEMO, thus strengthening the inhibitor of kB kinase (IKK) activation. SENP6 reverses this process by catalyzing the de-SUMOylation of NEMO. Our study highlights the essential function of the SENP family in dampening TLR signaling and inflammation.
Introduction
Toll like receptors (TLRs) are a family of membrane receptors that sense a wide range of invading pathogens, including bacteria, fungi and viruses. Upon activation, TLRs trigger innate immune responses and prime the adaptive immune system to eliminate the pathogens [1, 2] . However, the excessive activation of TLR signaling causes injuries to the host (inflammation and autoimmune diseases) [3] . Thus, the TLR signaling pathways are subjected to stringent regulations spatially and temporally.
TLR signaling triggers the activation of NF-kB, interferonregulatory factors (IRFs) and activator protein 1 (AP-1). These transcriptional factors coordinate to induce the expression of a broad range of proteins important in the immune and inflammatory responses [4, 5] . TLR-mediated activation of NF-kB depends on the activity of the inhibitor of NF-kB (IkB) kinase (IKK) complex. The IKK complex is composed of two related catalytic subunits, IKKa and IKKb, and a regulatory subunit, NF-kB essential modifier (NEMO/IKKc) [6, 7] . Although NEMO does not display catalytic activity, it is indispensable for the activation of the IKKa/b [8, 9] . Recent studies propose that NEMO contains the unique ubiquitin-binding domain, which recognizes the K63-linked and linear polyubiquitin chains and triggers IKK activation [10, 11] . Intriguingly, NEMO per se is modified by the polyubiquitin chain, which is also critical for the IKK activation [12, 13] . Notably, the deubiquitinase CYLD could interact with NEMO and cleave these polyubiquitin chains, thus acting as a negative regulator of NF-kB signaling [14] .
Interestingly, NEMO and IkBa are dynamically modified by SUMO-1 [15, 16] . The SUMO-1 modification of IkBa makes it resistant to the signal-induced degradation. It is intriguing to understand the potential function of the SUMOylation of NEMO, in particular, to address the synergistic or antagonistic effect between the ubiquitination and SUMOylation of NEMO. Futhermore, it remains unknown whether NEMO could be modified by SUMO-2/3 [17] .
Like ubiquitination, SUMOylation is a dynamic process, which involves three classes of enzymes: E1 activating enzyme (SAE1/ SAE2), E2 conjugating enzyme (Ubc9) and possibly E3 ligases. SUMOylation is reversed by a family of sentrin/SUMO-specific proteases (SENPs) [18, 19] . SENP family has six members (SENP1-3 & SENP5-7), each of which exhibits distinct expression patterns and substrate specificity [20, 21] .
Much is known about the biological functions of SENP1 and SENP2. For example, SENP1 and SENP2 could process newly synthesized SUMOs into their mature forms. SENP1 plays critical roles in the hypoxic responses, by reversing the SUMOylation of HIF1a and impairing the VHL protein to bind HIF1a, thus stabilizing HIF1a [22] . SENP2 modulates adipogenesis by the deSUMOylation and stabilization of C/EBPb [23] . SENP2 is essential for suppressing the polycomb group protein-mediated gene silencing, via targeting Pc2/CBX4, during embryonic development [24] . However, the physiological functions of the other SENPs are largely unknown, and this represents an emerging frontier for further investigation.
In this study, we report that SUMO-2/3 are conjugated onto the Lysine residue 277 of NEMO. This modification prevents the deubiquitinase CYLD from binding to NEMO and thus strengthens the IKK activation. SENP6 specifically reverses this process by catalyzing the de-SUMOylation of NEMO. Knockdown of SENP6 significantly potentiates the TLR-mediated induction of the proinflammatory genes. The in vivo 'knockdown' of SENP6 by siRNA confirms its critical role in tolerance to LPS in endotoxic shock models. This study reveals the essential function of SENP6 for dampening TLR-induced inflammation, shedding new light on the dynamic functions of the SUMOylation in innate immunity.
Results

Identification of SENP6 as a novel regulator of TLR signaling
To probe the potential function of the SUMO-specific proteases, we screened out individual siRNAs, which respectively diminish the expression of the corresponding SENPs (Fig. 1A, 1B and Fig. S1 ). An RNAi-based screening showed that the depletion of SENP6, rather than other members of the SENP family, apparently enhanced the TNF-a-induced activation of the kBluciferase reporter and the E-selectin-luciferase reporter, which are both tightly regulated by NF-kB (Fig. 1C) . Likewise, the activation of kB-luciferase reporter was apparently boosted upon SENP6 depletion in response to TLR4, TLR3 or TLR7 signaling in RAW264.7 cells when stimulated with extracellular LPS, poly (I:C), imiquimod (R837), respectively (Fig. 1D) .
A recent study suggested that SENP2 could potentially inhibit the NF-kB activation in response to DNA damage [25] , which is confirmed by us (Fig. 1E) . However, silencing of SENP6 apparently displayed no effect on the genotoxic-stress-induced NF-kB activation (Fig. 1E ). Neither could SENP6 influence the PMA-induced activation of the AP-1-luciferase reporter (Fig. 1F) . These data suggest that SENP6 may play a negative regulatory role for TLR signaling.
Knockdown of SENP6 potentiates TLR-mediated NF-kB activation
To substantiate, we explored the effect of SENP6 knockdown on the expression of the endogenous NF-kB-responsive genes induced by LPS, using qPCR (quantitative PCR) and ELISA (enzyme-linked immunosorbent assay). As expected, SENP6 knockdown markedly potentiated the induction of the NF-kBresponsive genes (IL-6, TNF-a, and ICAM-1), whereas SENP7 knockdown displayed no such effect ( Fig. 2A, Fig. S2 and Fig. S3 ).
In contrast, the induction of IRF3-responsive genes (ISG15 and ISG56) was unaffected by SENP6 depletion upon LPS stimulation (Fig. S4) . Consistently, in response to poly (I:C) or Sendai virus stimulation, knockdown of SENP6 resulted in augmented production of NF-kB-targeted cytokines as well ( Fig. S3 and Fig.  S5 ).
To rule out the potential off-target effects of the SENP6 siRNA, we generated several RNA interference (RNAi)-resistant SENP6 constructs, namely rSENP6 WT and rSENP6 C1030S (the catalytically inactive mutant which loses the de-SUMOylation activity, see below), in which silent mutations were introduced into the sequence targeted by the siRNA without changing the amino acid sequence of the corresponding proteins. MEF cells were first transfected with control or SENP6 siRNAs, followed by transfection of the control or indicated rSENP6 plasmids, respectively. Then, the induction of IL-6 mRNA was measured after LPS stimulation. As shown in Fig. 2B , the up-regulation of the IL-6 mRNA, in SENP6 knockdown cells, was reversed by introducing rSENP6 WT. But this is not reversed by rSENP6 C1030S. Collectively, these data indicate that SENP6 negatively modulates TLR-mediated NF-kB signaling, and this is dependent on its deSUMOylation activity.
To further elucidate the signaling node targeted by SENP6, we observed that LPS-induced TRAF6 auto-ubiquitination was not affected by endogenous SENP6 depletion (Fig. 2C) . In contrast, knockdown of SENP6 led to an apparent increase in the phosphorylation of IkBa and NF-kB p65, but not that of JNK (Fig. 2D) . Consistently, the nuclear translocation of p65, induced by LPS, was markedly accelerated when depleting the SENP6 (Fig. 2E ). In addition, we observed that exogenous expression of MyD88, TRAF6 or IKKb could respectively activate the kBluciferase reporters, and these activations were markedly potentiated when knocking down SENP6 (Fig. S6) . In contrast, SENP6 knockdown had no effect on the activation of the kB-luciferase reporter, when cells were stimulated with the exogenous p65 (Fig.  S6 ). Given the hierarchical relationships among these signaling molecules, we reasoned that SENP6 modulates NF-kB activation around the IKK protein complex.
NEMO/IKKc is specifically modified by SUMO-2/3
Biochemically, SENP6 has been characterized to preferentially remove SUMO-2/3 from the pseudo-substrate [20] . Given the observation that SENP6 modulates the NF-kB signaling via its deSUMOylation activity, we hypothesized that the IKK complex is a target for the SUMO-2/3 modification. To explore this possibility, IKKa, IKKb or NEMO was respectively co-expressed with SUMO-3 in HEK293T cells. The cell lysates were subjected to the denaturing immunoprecipitation of Flag (Fig. 3A) or the Ni-NTA pulldown of His-SUMO-3 (Fig. S7A) . Then the precipitates were probed with the indicated antibodies. Apparently, NEMO was robustly modified by SUMO-3, whereas neither IKKa nor IKKb could be modified by SUMO-3 ( Fig. 3A and Fig. S7A ).
Sequence alignment reveals that SUMO-2 and SUMO-3 are almost identical (,95% identical), whereas SUMO-1 is largely diverged (,45% identical) [20] . Indeed, besides SUMO-3, SUMO-2 could be conjugated onto NEMO as well ( Fig. 3B and Fig. S7B ). Additionally, this modification took place in a IKKa and IKKb-independent manner, as deletion of the N-terminal IKK-binding domain of NEMO [26] did not affect the SUMOylation of NEMO (Fig. 3C) . Furthermore, endogenous NEMO was confirmed to be SUMOylated as the above observations (Fig. 3D) . Interestingly, the SUMOylation of NEMO was markedly enhanced when stimulated respectively with LPS (TLR4 agonist), poly (I:C) (TLR3 agonist), or imiquimod R837
Author Summary
Given the double-edged nature of the TLR functions, the strength and duration of the TLR signaling are dynamically modulated via protein posttranslational modifications, which ensure that the invading microbes are quickly eliminated and the damages to the host are reduced to the minimum. Besides the ubiquitin, ubiquitin-like proteins are emerging as novel protein tags to fine-tune the TLR signaling. It is intriguing to explore how the SUMO-specific proteases (SENPs) contributes to balancing the SUMOylation status of the TLR signaling. Our study reveals that NEMO, a critical protein of the TLR signaling pathways, is covalently modified by SUMO-2/3. This modification is resversed by the de-SUMOylation activity of SENP6. Thus, SENP6 faciliates CYLD to bind NEMO and to remove the polyubiquitin chains on NEMO, ultimately dampening the IKK activation. This study sheds new light on the dynamic functions of the SUMOylation in restricting proinflammatory response.
(TLR7 agonist) ( Fig. 3D and Fig. S8 ). Taken together, these data indicated that exogenously expressed and endogenous NEMO can be targeted for SUMO-2/3 modification.
A highly conserved motif YKxD/E (where Y is a hydrophobic residue and x represents any residue) has been proposed as the SUMOylation sites for any given substrates [19] . We uncovered three putative SUMO conjugation sites on NEMO(K139, 277 and 285) through bioinformatics analysis. Then, we carried out a systematic lysine (K) to alanine (A) mutation scanning to identify the potential SUMOylation sites on NEMO. SUMO-3 was expressed along with the NEMO constructs harboring different K to A point mutations, followed by IP or Ni-NTA pulldown analysis. Whereas NEMO K139A and NEMO K285A were SUMOylated as well as the wild-type NEMO, the SUMOylation of the NEMO K277A was almost abolished (Fig. 3E and Fig.  S7C ), indicating that the K277 was the major acceptor site on NEMO for SUMO-3.
Alternatively, we generated the NEMO (3A) mutant, in which all of the three lysines (139, 277 and 285) were mutated to alanines. As expected, NEMO (3A) could barely be modified by potentiates TNF-a-induced NF-kB activation. 56kB-luciferase (left panel) or E-selectin-luciferase (right panel) and pTK-Renilla reporters were transfected into HEK293T cells together with the indicated siRNA. Forty-eight hours after transfection, cells were stimulated with TNF-a (10 ng/ml) for eight hours before luciferase reporter assays were performed. D, SENP6 potentiates TLR-triggered NF-kB activation. The nonspecific control (N.C.) or SENP6 siRNA were transfected into RAW264.7 cells with 56kB-luciferase and pTK-Renilla reporters. Forty-eight hours after transfection, cells were stimulated with LPS (1 mg/mL), poly (I:C) (50 mg/ml), R837 (10 mg/ml) for 8 h before luciferase assays were performed. E, SENP6 has no effect on the NF-kB activation in response to DNA damage. HEK293T cells were transfected with 56kB-luciferase and pTK-Renilla reporters together with the nonspecific control (N.C.), SENP6 siRNA or SENP2 siRNA. Forty-eight hours after transfection, cells were stimulated with doxorubicin (500 ng/ml) for eight hours before luciferase reporter assays were performed. F, SENP6 has no influence on the activation of AP-1. HEK293T cells were transfected with AP-1-luc and pTK-Renilla reporters together with the nonspecific control (N.C.) or SENP6 siRNA. Forty-eight hours after transfection, cells were stimulated with PMA (20 ng/ml) for eight hours before luciferase reporter assays were performed. Data from C-F are presented as means 6S.D. from three independent experiments. n.s., not significant; *, P,0.05; **, P,0.01. doi:10.1371/journal.ppat.1003480.g001 Fig. 3F and Fig. S7D ). On the background of this NEMO (3A) mutant, we generated three more NEMO mutants (K139, K277 or K285 respectively), in which a lysine residue was re-introduced back to the original site. We observed that, only when K277 was re-installed into the NEMO (3A) mutant could the SUMOylated band re-appeared ( Fig. 3F and Fig. S7D ). Collectively, these data firmly establish that the K277 of NEMO is both necessary and sufficient for the SUMO-3 modification. 
SUMO-3 (
SENP6 catalyzes the de-SUMOylation on the NEMO K277
Given that NEMO could be modified by SUMO-2/3, we speculated that the SUMOylated NEMO is a potential substrate of SENP6. To address this possibility, we analysed the catalytic center of the SENP family ( Fig. S9A ) and generated several SENP6 point mutants. The SENP6 C1030S (Cys to Ser mutation at 1030 residue) is the catalytically inactive mutant [27] ; whereas the SENP6 D1029E (Asp to Glu mutation at 1029 residue) is the catalytically active one, serving as a control.
A cell-based de-SUMOylation assay was performed to determine whether SENP6 could deconjugate the SUMOylated NEMO. The indicated SENP6, SENP3 or SENP7 construct was individually co-transfected with NEMO and SUMO-3. The cell lysates were subjected to immunoprecipitation of Flag-NEMO ( Fig. 4A and Fig. S10 ) or Ni-NTA pulldown of His-SUMO-3 ( Fig.   S9B ). Then the precipitates were probed with the indicated antibodies. As expected, NEMO was robustly SUMOylated in the presence of SUMO-3. Notably, this modification was drastically reduced by the expression of SENP6. In contrast, SENP6 C1030S, SENP3 as well as SENP7 could not influence the SUMOylation status of NEMO. In addition, SENP6 D1029E decreased the NEMO SUMOylation similar to that of the SENP6 (WT) (Fig. 4A and Fig. S9B ).
We went on to investigate whether SENP6 can remove the SUMO-3 modification on the NEMO K277. As expected, the NEMO K277 (see above) was modified by SUMO-3, as well as that of the NEMO (WT). Notably, the conjugation of SUMO-3 onto the K277 of NEMO was almost completely abolished in the presence of SENP6 (WT). In contrast, SENP6 C1030S could not influence the SUMOylation status of the NEMO K277 (Fig. 4B) . Furthermore, knocking down endogenous SENP6 could enhance the basal SUMOylation of Flag-NEMO, whereas knocking down endogenous SENP3 displayed no such effect (Fig. 4C) . Consistently, SENP6 knockdown apparently potentiated the SUMOylation of the endogenous NEMO (Fig. 4D) . Collectively, these data demonstrate that SENP6 deconjugates the SUMO-3 modification on the K277 of NEMO.
SENP6 selectively interacts with the SUMOylated NEMO
We noticed that SENP6 could not co-immunoprecipitate with NEMO per se. However, SENP6 could co-immunoprecipitate weakly with SUMO-3 alone (Fig. 5A) . This behavior is similar to many ubiquitin-like binding proteins, which bind to the ubiquitinlike fusion proteins (mimicking the constitutively modified state of a given substrate). So we generated the NEMO-SUMO-3 fusion protein, in which SUMO-3 was fused to the C-termini of NEMO. As shown in Fig. 5A , SENP6 interacts strongly with the NEMO-SUMO-3, as compared to SUMO-3 or NEMO alone. Furthermore, we explored the interaction between SENP6 mutants and the NEMO-SUMO-3. It was observed that NEMO-SUMO-3 could interact as well with SENP6 C1030S or SENP6 D1029E (Fig. 5B) . Notably, SENP6 C1030S displayed substantially improved binding affinity for NEMO-SUMO-3 ( Fig. 5B) , suggesting that the enzymatic activity of SENP6 is dispensable for its binding.
To map the critical domain for this interaction, a series of Myc tagged SENP6 deletion mutants (Fig. 5C , upper panel) were generated and individually transfected into HEK293T cells along with the NEMO-SUMO-3. It was observed that the N terminal domain of SENP6 (1-300 aa) mediated this interaction (Fig. 5C , lower panel).
To confirm that SENP6 does interact with the SUMOylated NEMO, the SUMOylated NEMO was generated and purified as shown in the experimental procedure (Fig. 5D, right panel) . Briefly, Flag-NEMO was co-expressed with His-SUMO-3 and the cell extracts were purified by Ni-NTA agarose and the eluate (,300 mM Imidazole) was subjected to GST-pulldown. Consistently, the GST-SENP6 could directly pull down the SUMOylated NEMO, whereas GST failed to do so. In addition, GST-SENP6 could not pull down anything from the NEMO K277A eluate (Fig. 5D, left panel) . Consistently, SENP6 was co-immunoprecipitated by either NEMO or NEMO K277 in the presence of SUMO-3 (Fig. 5E ). However, this does not apply to SENP7 (Fig.  S11) . Taken together, these data indicate that SENP6 could specifically interact with the SUMOylated NEMO, but not with NEMO per se.
SENP6 attenuates the action of NEMO in TLR-triggered NF-kB signaling
To explore the functional consequence of the SUMOylation of NEMO, we tested whether this modification will influence the composition of the NEMO protein complex. So, the SUMOylated NEMO or the NEMO-SUMO-3 fusion protein was produced and purified, and their interactions with other regulatory proteins were investigated (Fig. 6A) . Consistent with recent reports [14, 26] , both GST-CYLD (470-684 aa) and GST-IKKb (644-756 aa) could pull down the unmodified NEMO (Fig. 6B and 6C) . Strikingly, GST-CYLD (470-684 aa) could pull down neither the NEMO-SUMO-3 nor the SUMOylated NEMO (Fig. 6B , left panel and Fig. 6C ), whereas GST-IKKb (644-756 aa) could pull down both the NEMO-SUMO-3 and the SUMOylated NEMO (Fig. 6B , right panel and Fig. 6C ), indicating that the SUMO-3 modification specifically impaired the interaction between NEMO and CYLD. Indeed, knockdown of SENP6 impaired the endogenous association of NEMO and CYLD (Fig. 6D) . Furthermore, we found that polyubiquitination of NEMO, which activates the IKK complex, was markedly increased in the SENP6 depleted cells (Fig. 6E) . However, SENP6 depletion had no influence on the expression of CYLD (Fig. 6D) .
In addition, we investigated the role of the SUMO-2/3 modification of NEMO in the TLR signaling. So RNAi-resistant NEMO constructs, namely rNEMO WT or rNEMO K277A was individually employed to rescue LPS-induced NF-kB activation, in the NEMO-knockdown cells. Whereas rNEMO WT restored the induction of kB-luciferase reporter upon LPS stimuli, rNEMO K277A failed to rescue kB-luciferase induction (Fig. 6F) . Taken together, these data indicate that the SUMO-2/3 modification synergizes the activation of NEMO, and SENP6 attenuates the TLR-triggered NF-kB activation via catalyzing the de-SUMOylation of NEMO.
SENP6 is indispensable to protect mice against endotoxin shock in vivo
To address the in vivo function of SENP6 in dampening inflammation, we employed the mouse endotoxin shock model, in which mice are injected intraperitoneally with a sub-lethal dose of LPS, and then the inflammatory responses were evaluated [28] .
First, we delivered into mice, via tail vein injection, the SENP6 specific or control siRNAs coated with polyethyleneimine (PEI). The efficiency of in vivo 'knockdown' was confirmed (Fig. 7A) . Next, mice were injected intraperitoneally with LPS at 25 mg/kg (the sub-lethal dose), and their survival rates were monitored. As expected, SENP6-knockdown mice were more susceptible to endotoxin shock than control mice. All the SENP6-knockdown mice died within 30 hours, whereas 80% of the control mice remained alive (Fig. 7B) . Furthermore, we examined the proinflammatory cytokine production of the SENP6 'knockdown' mice in vivo. Consistently, the LPS-induced cytokines (TNF-a and IL-6) were significantly elevated in the plasma of the SENP6-knockdown mice (Fig. 7C) . In addition, the expression of TNF-a and IL-6 mRNAs was higher in liver tissues from the SENP6-knockdown mice (Fig. 7D) . Apparently, knockdown of SENP6 in vivo does not affect cell proliferation (Fig. S12) . Collectively, these data suggest that SENP6 is indispensable for protecting mice against endotoxin shock.
Discussion
Given the critical functions of TLR signalings in immunity, they are stringently modulated in a multi-layered and highly-ordered manner, so as to ensure that the strength and duration of the TLR signal is appropriate for any given immune response. The dynamic regulations are mainly realized by the protein post-translational modifications, in response to the intrinsic and environmental cues.
Besides phosphorylation, it is recently well established that TLR signaling molecules (TRAFs, RIPs, IRAKs, IKKs, IkBs, Rels, IRFs) are extensively regulated by ubiquitination [29, 30] . To counterbalance, A20, CYLD, OTUB1, OTUB2, Cezanne, and YopJ are implicated in promoting the de-ubiquitination of these signaling proteins [14, 31, 32, 33, 34, 35] . However, it remains a great challenge to elucidate in vivo, the functional relationship among these modifications, as well as the corresponding molecular mechanisms of the conformational switches. Interestingly, SUMO, the ubiquitin-like protein, is also emerging as the active modulator of the TLR signaling. For example, SUMO-1 could covalently attach itself onto TANK upon TLR7 stimulation, and this relieves the inhibition of TANK towards TLR7 signaling [36] . In addition, previous studies demonstrated that SENP1 and SENP2 could HEK293T cells were transfected with the indicated plasmids. When HA-NEMO (Sample 1) or HA-NEMO-SUMO-3 (Sample 2) was expressed alone, the cell extracts were subjected directly to GST-PD analysis. When HA-NEMO was co-expressed with His-SUMO-3, the cell extracts were firstly purified by Ni-NTA agarose. Then the Ni-NTA-bound His-SUMO-3 modified proteins were eluted by imidazole (,300 mM), and the elute fractions were subjected to GST-PD analysis (Sample 3). B, HEK293T cells were transfected with HA tagged NEMO or NEMO-SUMO-3, and then equal amounts of cell lysates were subjected to GST-PD as indicated according to the experimental design described in A. C, HEK293T cells were transfected with HA-NEMO together with His-SUMO-3. The His-SUMO-3 modified proteins purified from the cell extracts were analyzed by GST-PD analysis as indicated according to the experimental design described in A. The SUMOylated and unmodified HA-NEMO were indicated on the right. D, SENP6 depletion abrogates the endogenous interaction between NEMO and CYLD. After mock or LPS (1 mg/ml) stimulation, lysates from MEF cells were immunoprecipitated with anti-NEMO antibody or anti-IgG and then immunoblotted with an anti-CYLD antibody. The intensity of the CYLD bound to NEMO was quantified regulate the activation of IRF8 and IRF3, respectively [37, 38] . It remains to address the functions and mechanisms of the deSUMOylation in TLR signaling. In particular, the physiological functions of other SENPs are largely unknown and this represents an evolving frontier for further investigation.
In this study, we demonstrate that SENP6 negatively regulates TLR-induced NF-kB signaling. Several lines of evidence substantiate this claim. Since IKKa/b interact with the N-termini of NEMO, the SUMOylation of NEMO does not influence the binding affinity among IKKa/b/c. In addition, the NEMO SUMOylation site does not overlap with its CYLD-binding domain. However, the SUMOylation effectively impairs the interaction between NEMO and CYLD, suggesting that the SUMO-moiety (,12 kDa) might directly mask the binding surface. Another possibility is that the SUMOylation triggers a corresponding conformational change on NEMO, thus abolishing their interaction. Interestingly, SENP6 displays weak affinity towards SUMO-3 alone. We speculate that the selectivity of SENP6 to the SUMOylated NEMO may be initated by interaction bewteen SUMO-3 and SENP6, and this is further consolidated by the conformational change induced by the SUMOylation, which probably forms a new binding surface on NEMO. Future structural analysis will hopefully provide insights to the putative mechanism. Taken together, our study reveals that NEMO is modified by SUMO-2/3. This modification synergizes the polyubiquitination of NEMO and the activation of IKK kinases, via preventing the access of CYLD to the IKK complex. To counterbalance, SENP6 reverses this synergy between the SUMOylation and ubiquitination of NEMO, via removing SUMO-3 from NEMO, thus facilitating the recruitment of CYLD and attenuating the IKK activation (See Fig. 7E ).
Our current model of the SENP6 action substantiates the dynamic function of the ubiquitination in regulating IKK activation, establishing a functional link between the ubiquitination and SUMOylation. SUMOylation could promote or antagonize the ubiquitination of a given substrate, depending on the topology of the modification sites. For example, the SUMOylation of HIF1a induced by hypoxia leads to its polyubiquitination and proteasome-mediated degradation, whereas IkBamodified by SUMO-1 is resistant to ubiquitin-mediated degradation [16, 22] .
To our knowledge, SENP6 represents the first case that the deSUMOylation facilitates the binding of a specific deubiquitinase.
The SUMO modification is highly dynamic, and it is catalyzed antagonistically by SUMO E2/E3 ligases and SENPs. It is not known about the identity of the potential E3 that catalyzes the SUMO-2/3 conjugation onto NEMO. It is speculated that Ubc9 (E2) is sufficient for this conjugation. SENP6 catalyzes the deconjugation of SUMO-3 from NEMO. In contrast, SENP1, SENP2 or SENP3 did not influence NEMO SUMOylation. Neither could any of them modulate the NF-kB activation stimulated by TLRs, highlighting the functional importance of SENP6 in inflammation and immunity. Interestingly, SENP6 has a unique insertion, not found in other SENPs, that splits the conserved catalytic domain. Whether this motif functions as a substrate determinant remains to be explored by structural analysis.
SENP6 (also named SUSP1), was recently identified as the largest member (1112 amino acids) of the SUMO-specific proteases family (the C48 cysteine proteases) [39] . Little is known about the physiological functions of SENP6, although the biochemical properties of SENP6 is established. It is recently suggested that SENP6 could modulate the SUMOylation of CENP-1 and PML. However, the underlying mechanism and functional consequences need further exploration. In addition, SENP6 could potentially modulates the SUMOylation status of RPA70, a pivotal factor for DNA repair [27] . In this study, we have linked SENP6 to dynamically regulate the IKK activation. Future studies will be focused on generating the SENP6 knockout mice and analyzing its critical function in immunity and inflammation. Biophysical approach will also be employed to probe the transient ubiquitination and SUMOylation status of NEMO, linking them to the activation status of IKK and NF-kB. and normalized to that of the corresponding immunoprecipitated NEMO. The relative levels of co-immunoprecipitated CYLD are shown as fold change compared with the control. E, SENP6 inhibits LPS-induced attachment of polyubiquitin chains onto NEMO. MEF cells were transfected with the nonspecific control (N.C.) or SENP6 siRNA and then treated with LPS (1 mg/mL). Cell lysates were immunoprecipitated with anti-NEMO and analyzed by immunoblotting using anti-ubiquitin (Ub). F, Modification of NEMO by SUMO-3 is required for the activation of NF-kB. RAW264.7 cells were transfected with the nonspecific control (N.C.) or NEMO siRNA together with 56kB-luciferase and pTK-Renilla reporters, as well as the indicated siRNA-resistant NEMO constructs. After LPS (1 mg/ml) stimulation, cell lysates were prepared for luciferase assay. Data from F are presented as means 6 S.D. from three independent experiments. *, P,0.05; **, P,0.01. doi:10.1371/journal.ppat.1003480.g006
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Reagents
The polyclonal antibody against SENP6 was a gift from Dr. Ronald T. Hay (University of Dundee, U.K.). Mouse anti-SENP6 antibody was obtained from Abnova. The antibodies against hemagglutinin (HA), Myc, NEMO, CYLD and SENP3 were purchased from Santa Cruz Biotechnology. Flag, His, Ub and bactin antibodies were obtained from Sigma-Aldrich. SUMO-2/3 antibody was purchased from Zymed. Phospho-IkBa, phospho-NF-kB p65 and phospho-JNK antibodies were from Cell Signaling. Human recombinant TNF-a was purchased from R&D Systems (Minneapolis, MN) . N-ethylmaleimide (NEM), phorbol 12-myristate 13-acetate (PMA), Doxorubicin (DOX) Figure 7 . Mice deficient in SENP6 are more susceptible to LPS induced endotoxic shock. A, Immunoblot analysis of SENP6 in lysates of kupffer cells from mice at forty-eight hours after transfection with SENP6 or nonspecific (N.C.) siRNA. B, Survival of mice (n = 10 per group) transfected with SENP6 or control siRNA and forty-eight hours later injected intraperitoneally with LPS (25 mg/kg). C, ELISA of TNF-a and IL-6 in serum from mice (n = 8 per group) transfected with SENP6 or control siRNA and seventy-two hours later injected intraperitoneally with LPS (25 mg/kg), assessed two hours after LPS injection. D, Quantitative PCR of relative TNF-a and IL-6 mRNA in livers from mice (n = 7 per group) transfected with SENP6 or control siRNA and seventy-two hours later injected intraperitoneally with LPS (25 mg/kg), assessed two hours after LPS injection. Data from C-D are presented as means 6S.D. from three independent experiments. *, P,0.05; **, P,0.01. E, A schematic model of the SENP6 function in TLR signaling. The deubiquitinase CYLD acts as a negative regulator of TLR signaling by interacting with NEMO and cleaving polyubiquitin chains. SUMO-2/3 could be conjugated onto NEMO, which prevents CYLD from binding to NEMO, thus strengthening the IKK activation. SENP6 reverses this process by catalyzing the de-SUMOylation of NEMO. doi:10.1371/journal.ppat.1003480.g007
and LPS were purchased from Sigma-Aldrich. The complete protease inhibitor cocktail and the PhosSTOP phosphatase inhibitor cocktail were obtained from Roche. The siRNA duplexes targeting SENPs and NEMO were chemically synthesized by Gene-Pharma. The sequences of siRNAs are shown as follows: mSENP6-1#, 59-GGG UGA UAA AGC CUG UAA ATT-39; mSENP6-2#, 59-CAA CUA AUC UGU CGA UAC ATT-39; mSENP7-1#, 59-GGA CGA GAA UUC AGA AAG ATT-39; mSENP7-2#, 59-GCC UUA UGC UCU UAG AAA UTT-39; hSENP1, 59-GUG AAC CAC AAC UCC GTA UUC-39; hSENP2, 59-GGG AGU GAU UGU GGA AUG UTT-39; hSENP3, 59-GCU UCC GAG UGG CUU AUA ATT-39; hSENP5, 59-GUC CAC UGG UCU CUC AUU ATT-39; hSENP6, 59-GAC UUA ACA UGU UGA GCA ATT-39; hSENP7, 59-CAA AGU ACC GAG UCG AAU AUU-39; NEMO, 59-CCA UGA GUC AGC CAG GAU UTT-39; The nonspecific siRNA (N.C.), 59-UUC UCC GAA CGU GUC ACG UTT-39.
Plasmids and recombinant proteins SENP1, SENP2, SENP3, SENP5, SENP6, SENP7, MyD88, TRAF6, p65, IKKa, IKKb, NEMO, CYLD cDNAs were obtained by PCR from the thymus cDNA library and subsequently inserted into mammalian expression vectors as indicated. The reporter plasmids (56kB-luciferase, E-selectinluciferase, AP-1-luciferase and pTK-Renilla) have been described previously [40] . SUMO-2, SUMO-3 constructs were kindly provided by Dr. Jinke Cheng (School of Medicine, Shanghai Jiao Tong University, Shanghai, China). The SENP6 siRNA-resistant form was generated with silent mutations introduced into the siRNA target sequence. All point mutations were generated by using a QuickChange XL site-directed mutagenesis method (Stratagene). All the plasmids were verified by sequencing. Recombinant GST-fusion proteins were purified from Escherichia coli (BL21) by using glutathione-Sepharose 4B resin (GE Healthcare, Piscataway, NJ).
Immunoprecipitation assay and immunoblot analysis
For immunoprecipitation assay, cells extracts were prepared by using RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) supplemented with a complete protease inhibitor cocktail (Roche) and 20 mM N-ethylmaleimide (NEM). Lysates were incubated with the appropriate antibody for four hours to overnight at 4uC before adding protein A/G agarose for two hours. The immunoprecipitates were washed three times with the same buffer and eluted with SDS loading buffer by boiling for five minutes.
For denaturing immunoprecipitation, cells were lysed in 1% SDS buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% SDS, 10 mM DTT) and boiled for thirty minutes. The lysates were centrifuged and diluted by 10-fold with Lysis buffer (50 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100). The diluted lysates were immunoprecipitated with the indicated antibodies for four hours to overnight at 4uC before adding protein A/G agarose for two hours. After extensive wash, the immunoprecipitates were subjected to immunoblot analysis.
For immunoblot analysis, the samples were subjected to SDS-PAGE. The resolved proteins were then electrically transferred to a PVDF membrane (Millipore). Immunoblotting was probed with indicated antibodies. The protein bands were visualized by using a SuperSignal West Pico chemiluminescence ECL kit (Pierce). Signal intensities of immunoblot bands were quantified by Image J software.
Ni-NTA pulldown analysis
For Ni-nitrilotriacetic acid resin (NTA) pulldown analysis, cells were lysed in His-Lysis Buffer (50 mM Tris-HCl pH 7.4, 300 mM NaCl, 1% Triton X-100, 20 mM imidazole, 10 mM b-ME) supplemented with 1 mM PMSF. After centrifugation, the supernatants were collected and incubated with 20 mL Ni-NTA agarose beads (Qiagen) for four hours at 4uC. The precipitates were washed three times with His-Lysis Buffer, and were boiled with SDS loading buffer, and then subjected to SDS-PAGE followed by immunoblot analysis.
GST pulldown analysis
For GST pulldown analysis, purified recombinant GST-fusion proteins were bound to GST resin (GE Healthcare) by incubating for two hours followed by extensive washing. Cell extracts were prepared by the similar method as immunoprecipitation analysis. The preloaded GST resin were added into the cell extracts and then incubated for four hours at 4uC. Precipitates were extensively washed before loading onto SDS-PAGE. The indicated proteins were revealed by immunoblot analysis.
Luciferase reporter assays
Luciferase reporter assays were performed as described previously [41] . 
Real-time RT-PCR
Measurement of cytokines
Concentrations of the cytokine in culture supernatants were measured by ELISA kit (R&D Systems) according to the manufacturer's instructions.
Immunostaining and confocal microscopy
Cells grown on coverslips were fixed for 15 min with 4% paraformaldehyde in PBS, permeabilized for 20 min in 0.1% Triton X-100 in PBS and blocked using 5% BSA for 1 hour. Then, the cells were stained with the indicated primary Abs followed by incubation with a Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch). Nuclei were counterstained with DAPI (Sigma-Aldrich). Slides were mounted using Aqua-Poly/ Mount (Polysciences, Warrington, PA). Images were captured at room temperature using a confocal microscope (TCS SP2 ACBS; Leica) with a 663 (numerical aperture 1.4) oil objective. The acquiring software was TCS (Leica, Solms, Germany).
In vivo siRNA transfection and in vivo endotoxic shock model
The siRNA was delivered into C57BL/6 mice with JetPEI transfection reagent (PolyPlus Transfection, San Marcos, CA) according to the manufacturer's instructions. The siRNA and JetPEI was each diluted into 100 ml of 5% glucose, then mixed and incubated for fifteen minutes at room temperature at a final N/P ratio of 8. Finally, the mixture (200 ml) was injected into each mouse via tail vein.
For the LPS-induced endotoxicity study, after seventy-two hours of siRNA delivery in vivo, the mice were challenged intraperitoneally with LPS at a dose of 25 mg/kg. Then, two hours later, relative mRNA in livers was measured by quantitative real-time RT-PCR. Cytokines IL-6 and TNF-a from SENP6-knockdown or control mice were also measured two hours after intraperitoneal injection of LPS (25 mg/kg) by ELISA kits (R&D Systems) according to manufacturer's instructions.
For the LPS-induced endotoxic shock study, mice were injected intraperitoneally with 25 mg/kg LPS after forty-eight hours of in vivo siRNA transfection. The mice were monitored for lethality for the ensuing thirty hours.
For analysis of in vivo 'knockdown' efficiency, mice were euthanized after forty-eight hours of in vivo siRNA transfection and then extracts of kupffer cells from livers were prepared for immunoblot analysis.
Isolation and purification of Kupffer cells
Kupffer cells were harvested as previously reported [42, 43] . Briefly, the C57/BL6 mice were anaesthetized by intraperitoneal injection of 6 mg/ml sodium pentobarbital in saline (0.06 mg/g body weight). Then, the liver was cannulated via the portal vein, and perfused with calcium-and magnesium-free HBSS. This was followed by perfusion with HBSS containing 0.1% type IV collagenase (Worthington Biochemical Corporation). The liver was then excised and the cells dispersed in RPMI1640. The homogenate was filtered through a 70 mm cell strainer (BD Biosciences) and centrifuged at 50 g for 5 min to pellet the liver cells. Subsequently, the supernatant containing non-parenchymal liver cells was re-centrifuged at 300 g for 10 min. The cell pellet was then resuspended in 10 ml RMPI 1640, loaded onto 25% and 50% Percoll gradients, and centrifuged at 1400 g for 30 min. The cells at the interface were washed and resuspended in RMPI 1640. Kupffer cells were enriched by selective adherence to tissue culture plates.
Cell cycle analysis
Preparations of cell suspensions for cell cycle analysis were performed as previously described [44] . Briefly, cells were fixed in ice-cold 70% ethanol at 4uC. After being washed with PBS twice, DNA was stained with 20 mg/mL propidium iodide (SigmaAldrich) in the presence of 200 mg/mL RNase A (Fermentas). Data were acquired on a FACSCalibur (BD Biosciences) and analyzed using CellQuest (BD Biosciences) and FlowJo (TreeStar Inc.).
Statistics
Student's t-test was used for statistical analysis; P values of less than 0.05 were considered statistically significant.
Accession numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession numbers for the genes and gene products discussed in this paper are: SENP6 (NM_146003. 
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